About Investor Relations

Building the trust layer for Ayurveda

For serious investors evaluating Indian healthcare-tech opportunities with international optionality. Below: our market read, position, and how to engage.

The investment thesis in one paragraph

Indian Ayurveda is mainstreaming — 40%+ of urban Indian patients now use AYUSH at least occasionally, the market grew at 17% CAGR through 2024, and international medical tourism to India is on track to cross $13B. Yet the consumer trust layer is broken: roadside “Ayurveda spas”, unverified practitioners, miracle-cure marketing, and zero accountability dominate the consumer-facing experience. AyurConnect is the verified directory + knowledge platform + AI tooling layer that solves this — and we are positioning to be the durable trust infrastructure on top of which marketplace, HMS, LMS, and white-label SaaS revenue lines scale.

Market context

$10.2 B

Indian Ayurveda market (TAM)

2024, growing 17% CAGR

$13.4 B

Global medical tourism (India share)

Kerala captures ~30% of India-bound flows

40%+

Indian patients seeking AYUSH

Of urban population, 2024 IBEF data

500,000+

BAMS practitioners registered with CCIM

Across India

600+

Kerala AYUSH-graded centres

AYUSH Premium/Silver/Gold/Diamond

Source notes available on request. Market values referenced from IBEF, Ministry of AYUSH, and industry reports.

Our four moats

Verified directory + content moat

Every doctor cross-checked against CCIM register, every page reviewed by clinical advisors. We refuse paid placement. The result: the most trustworthy Ayurveda directory in India — a long-term moat that mass-market wellness platforms cannot replicate without rebuilding from scratch.

Two strong demand vectors

Domestic: 1.4 billion-strong market where Ayurveda is rapidly mainstreaming into preventive + chronic-disease care. International: $13B and growing global medical-tourism flow to India — Kerala is the gold-standard for classical Ayurvedic treatment, and AyurConnect is the trusted gateway.

Multi-product roadmap

Today: verified directory, AyurBot AI, Prakriti analyzer, treatment guides, lead pipeline. Next 18 months: full marketplace (vendor portal + e-commerce), white-label SaaS for hospital chains, Ayurveda-native HMS, Academy (BAMS + Panchakarma + CME courses). Each is a multi-year revenue line.

Regulatory discipline

We engage proactively with AYUSH and CCIM. Compliance with Drugs & Magic Remedies Act, IT Rules 2021 intermediary safe-harbour, DPDP Act 2023 patient data protection. International expansion plan accounts for FDA / MHRA / Saudi FDA equivalents for any tools we ship into those markets.

What we are NOT

Investor due diligence is faster when expectations are set. AyurConnect is deliberately not:

Not: A wellness-influencer content shop
We refuse paid placement and reject mass-market wellness positioning. The audience that comes to us comes for verification, not entertainment.
Not: An aggregator selling unverified practitioners
Every listed doctor's CCIM number is cross-checked annually. We de-list on disciplinary action within 48h.
Not: A pharma-distribution play
We connect patients to verified GMP-certified vendors but do not take title or inventory. Marketplace will operate on commission, not arbitrage.
Not: An IVF / chronic-care clinic
We are the trust + tooling + tooling-on-tooling layer. Hospitals deliver care; we route patients to them and equip them with software.
Not: A pure-marketing-channel play
Long-term value sits in tooling (HMS, SaaS, marketplace, Academy) where switching costs accrue. Directory + AI are the front door.

What we will + will not share at first contact

Open

• Audited financials at appropriate stage
• Verified-doctor + verified-hospital counts
• Web platform metrics (sessions, conversion)
• Regulatory positioning + compliance status
• Product roadmap by quarter
• Team CVs + advisory board details

Held until NDA + due diligence

• Patient-level data (DPDP Act protected)
• Doctor commercial agreements
• Pilot-partner contractual specifics
• Proprietary clinical advisory feedback loops
• Engineering-architecture deep-dive
• Acquisition target conversations

Engage

Serious investor inquiries: [email protected]. Please include your fund / family-office name, stage focus, cheque size band, and 1–2 portfolio comparables.

Contact form (general)

Note: This page is a public investor primer, not an offering. AyurConnect is not currently soliciting general investment. Formal due diligence + offering materials (if and when issued) will be shared privately under NDA per SEBI / SEC equivalents in relevant jurisdictions.